FDA imposes heart attack, stroke warnings on testosterones
This article was originally published in Scrip
The FDA on 3 March said it was imposing new warnings on the labeling of testosterone replacement therapies (TRTs), like AbbVie's $1bn drug AndroGel, about an increased risk of heart attack and stroke.
You may also be interested in...
While Lipocine Inc. is at the nail-biting stage of development for its oral testosterone Tlando (LPCN 1021) – awaiting a US FDA approval decision – urologists continue to study testosterone therapy to determine whether treatment of hypogonadal men is safe with appropriate monitoring.
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.